Acute Myeloid Leukemia: Evolving Through Targeted Therapies

Acute Myeloid Leukemia: Evolving Through Targeted Therapies

Episodes

Specialty:

All

Year:

All

EP. 1: FLT3 Genetic Alterations in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 2: FLT3-Mutated AML: Early Aggressive Therapy vs Transplant

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 3: FLT3-Mutated AML: Midostaurin and Chemotherapy

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 4: Second-Generation FLT3 Inhibitors in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 5: Utilization of Second-Generation FLT3 Inhibitors in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 6: VIALE Studies in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 7: Optimal Use of Venetoclax in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 8: Venetoclax in AML: Safety Profile

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 9: Monitoring Response to Venetoclax Regimens in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 10: FLT3 Triplet Regimens for AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 11: IDH Mutations in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 12: IDH1/2 Inhibitors for AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 13: IDH Inhibitors and MDS

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 14: Differentiation Syndrome and IDH Inhibitors in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 15: CPX-351 in Newly Diagnosed Secondary AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 16: Gemtuzumab for AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 17: CC-486 Maintenance Therapy in AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 18: Implications for Treating AML With CC-486

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

EP. 19: Progress in the Treatment of AML

ByHarry P. Erba, MD, PhD, Duke University School of Medicine,Amir Fathi, MD, Massachusetts General Hospital,Mark J. Levis, MD, PhD, Johns Hopkins University,Gail J. Roboz, MD, Weill Cornell Medical Center,Daniel Pollyea, MD, MS, University of Colorado Denver

July 20th 2020

Trending on OncLive

ASCO Guideline Update Broadens First-Line Treatment Options for HER2+ Gastroesophageal Cancer

ASCO Issues First Guideline on ctDNA Testing in Solid Tumors and Lymphoma

Dr Wainberg on INCB161734 Activity in Refractory Pancreatic Cancer

European Commission Approves Teclistamab Plus Daratumumab for R/R Myeloma

CAR T-Cell Therapy Continues to Make Its Case in Early Relapsed Myeloma